RECOMMENDED PRODUCTS
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 822222 | SEP-363856 HCl ( SEP-856 ) | 1310422-41-3 (HCl) | ≧98.0% | .png) |
| SEP-363856 is a novel trace amine receptor 1 (TAAR1) agonist with serotonin 5-HT1A ac | ||||
| 171553 | Anle138b | 882697-00-9 | ≧98.0% |  |
| Anle138b is an oral, brain-penetrant, general inhibitor of protein aggregation. It wa | ||||
| 171462 | MRTX0902 | 2654743-22-1 | ≧98.0% |  |
| MRTX0902is a potent SOS1 inhibitor which can be used for the therapeutic intervention | ||||
| 171652 | EZM0414 | 2411748-50-8 | ≧98.0% |  |
| EZM0414 is a potent, selective, and orally bioavailable inhibitor of SETD2. | ||||
| 122622 | CNS004 | 695205-24-4 | ≧98.0% |  |
| CNS004 is a novel compound that potentiates NMDA receptor currents based on glutamate | ||||
| 52014 | NXY-059 ( Disufenton Sodium ) | 168021-79-2 | ≧98.0% | .png) |
| NXY-059 ( Disufenton Sodium ) is a disulfonyl derivative of phenyl-tert-butyl nitrone | ||||
| 20449 | Ervogastat (PF-06865571) | 2186700-33-2 | ≧98.0% |  |
| Ervogastat (PF-06865571), a systemically acting diacylglycerol acyltransferase (DGAT2 | ||||
| 232251 | Brepocitinib ( PF-06700841 ) | 1883299-62-4 | ≧98.0% |  |
| Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1 | ||||
| 20460 | Ro5-3335 | 30195-30-3 | ≧98.0% |  |
| Ro5-3335 is a lipophilic small molecule RUNX1 inhibitor. | ||||
| 233901 | RRX-001 | 925206-65-1 | ≧98.0% |  |
| RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor a | ||||
| 230401 | Glycerol phenylbutyrate ( HPN-100 ) | 611168-24-2 | ≧98.0% |  |
| Glycerol phenylbutyrate, also known as HPN-100, is under trials in the treatment of c | ||||
| 232252 | Brepocitinib Tosylate | 2140301-96-6 | ≧98.0% |  |
| Brepocitinib ( PF-06700841 ) is an orally available, selective inhibitor of non-recep | ||||